Keywords: فاکتور Xa; Factor Xa; Protease-activated receptor-2; Pressure overload; Fibrosis; Atrial fibrillation;
مقالات ISI فاکتور Xa (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: فاکتور Xa; Hydrogel; Bioresponsive; Anticoagulation; Thrombin; Factor Xa;
Keywords: فاکتور Xa; AF; atrial fibrillation; INR; international normalized ratio; factor Xa; activated factor X; DOACs; direct-acting oral anticoagulants; RCTs; randomized controlled trials; RE-LY; Dabigatran Randomized Evaluation of Long-Term Anticoagulant Therapy; ROCKET-A
Keywords: فاکتور Xa; Factor Xa; Anticoagulant; Conjugation; Docking study;
Keywords: فاکتور Xa; AT; Antithrombin; serpin; Serine protease inhibitor; FXa; Factor Xa; RCL; Reactive center loop; Arg; Arginine; Lys; Lysine; VTE; Venous thromboembolism; type II RS; Type II reactive site defects; type II HBS; Type II heparin binding site defects; type II
International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs
Keywords: فاکتور Xa; ACC; accuracy; bpm; beats per minute; CI; confidence interval; CLSI; Clinical Laboratory Standards Institute; DVT; deep venous thrombosis; dx; diagnosis; ED; emergency department; fXa; factor Xa; HR; heart rate; N; number; ng/ml; nanograms per milliliter;
Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node
Keywords: فاکتور Xa; Atrial fibrillation; Factor Xa; Late sodium current; Pulmonary vein; Protease-activated receptor;
Padua FIXa resistance to Protein S and a potential therapy for hyperactive FIXa
Keywords: فاکتور Xa; Factor IXa; Padua factor IXa; Protein S; Thrombophilia; TGA; Factor Xa;
The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction
Keywords: فاکتور Xa; Cardiac remodeling; Coagulation; Factor Xa; Myocardial infarction; Protease-activated receptor; Rivaroxaban;
Structural analysis and biological activity of a highly regular glycosaminoglycan from Achatina fulica
Keywords: فاکتور Xa; GAG; glycosaminoglycan; LMWH; low-molecular-weight heparin; DS; dermatan sulfate; TSP; trimethylsilyl-propionic acid; GlcA; glucuronic acid; GlcNAc; N-acetyl-2-deoxy-2-amino-glucose; IdoA; iduronic acid; IdoA2S; 2-sulfated iduronic acid; Mw; molecular wei
Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition
Keywords: فاکتور Xa; Factor Xa; Active site; Exosite; Inhibition; AcAP5; Computational simulation;
ReviewAdvances in oral anticoagulation therapy - What's in the pipeline?
Keywords: فاکتور Xa; Activated factor X inhibitor; Factor Xa; Anticoagulation therapy; Venous thromboembolism; Novel oral anticoagulants;
Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay
Keywords: فاکتور Xa; AE; Adverse events; aPTT; activated partial thromboplastin time; ANOVA; Analysis of variance; CI; Confidence interval; DOACs; Direct oral anticoagulants; FDA; Food and Drug Administration; FXa; Factor Xa; GLSM; Geometric least squares means; LC/MS/MS; Liq
Recombinant expression of Ixolaris, a Kunitz-type inhibitor from the tick salivary gland, for NMR studies
Keywords: فاکتور Xa; Anticoagulant; Ixolaris; Factor Xa; Tissue factor; Tick saliva; NMR;
Anti-factor Xa activities of zingerone with anti-platelet aggregation activity
Keywords: فاکتور Xa; Zingerone; Factor Xa; Platelet aggregation; Noncompetitive inhibition model; Thrombosis;
Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry
Keywords: فاکتور Xa; Dual-target; Inhibitor screening; UHPLC-MS/MS; Thrombin; Factor Xa;
Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors
Keywords: فاکتور Xa; Factor Xa; Anticoagulant; fXa inhibitor; Arteriovenous shunt; Bleeding risk; Thromboembolic diseases;
A common polymorphism decreases LRP1 mRNA stability and is associated with increased plasma factor VIII levels
Keywords: فاکتور Xa; (LRP1); lipoprotein receptor-related protein 1; (FVIII); factor VIII; (AIS); acute ischemic stroke; (SNPs); single-nucleotide polymorphisms; (NMD); nonsense-mediated decay; (FIXa); factor IXa; (FX); factor X; (FXa); factor Xa; (vWF); von Willebrand factor
Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux
Keywords: فاکتور Xa; AUC5Â min; area under the curve of 5Â min-aggregation response; DMSO; dimethyl sulfoxide; F1Â +Â 2; prothrombin fragment F1Â +Â 2; FXa; factor Xa; IC50; 50% inhibition concentration; PPP; platelet-poor plasma; PRP; platelet-rich plasma; SEM; standard erro
Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician
Keywords: فاکتور Xa; novel oral anticoagulants; dabigatran; rivaroxaban; edoxaban; apixaban; direct thrombin inhibitor; factor Xa; atrial fibrillation; activated charcoal; prothrombin complex concentrates; vitamin K antagonists; warfarin; recombinant factor VIIa; idarucizumab
Interactions between depolymerized fucosylated glycosaminoglycan and coagulation proteases or inhibitors
Keywords: فاکتور Xa; FG; fucosylated glycosaminoglycan; dFG; depolymerized fucosylated glycosaminoglycan; UFH; unfractionated heparin; LMWH; low molecular weight heparin; FXase; factor Xase; AT; antithrombin; FIIa; thrombin; FXa; factor Xa; FIXa; factor IXa; BLI; biolayer int
Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo
Keywords: فاکتور Xa; PT; prothrombin time; aPTT; activated partial thromboplastin time; MS/MS; tandem mass spectrometry; FVa; active factor V; FVIIa; active factor VII; FII; prothrombin; PRP; Human platelet-rich plasma; ER; endoplasmic reticulum; ROS; reactive oxygen species;
Contemporary developments in the discovery of selective factor Xa inhibitors: A review
Keywords: فاکتور Xa; Thrombosis; Factor Xa; FXa inhibitors;
Design, synthesis and evaluation of isoxazolo[5,4-d]pyrimidin-4(5H)-one derivatives as antithrombotic agents
Keywords: فاکتور Xa; Antithrombotic agent; Factor Xa; Isoxazolo[5,4-d]pyrimidin-4(5H)-one; Docking
Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists
Keywords: فاکتور Xa; ADP; adenosine diphosphate; AF; atrial fibrillation; AM-clopidogrel; active metabolite of clopidogrel; DMSO; dimethyl sulfoxide; ETP; endogenous thrombin potential; FXa; factor Xa; mRate; mean thrombin generation rate; NOAC; Non-vitamin K oral anticoagula
Research PaperAqueous extract from Brownea grandiceps flowers with effect on coagulation and fibrinolytic system
Keywords: فاکتور Xa; BGE; Brownea grandiceps flowers aqueous extract; CI; confidence interval; FXa; Factor Xa; Fg; fibrinogen; FgC; fibrinogen control; FN; fibronectin; FNC; fibronectin control; g; grams; g; gravity; h; hour; L; liters; m; meters; min; minutes; MW; molecular
Identification of anthranilamide derivatives as potential factor Xa inhibitors: Drug design, synthesis and biological evaluation
Keywords: فاکتور Xa; Factor Xa; FBDD; Structure-based pharmacophore; Consensus docking; Prothrombin time; Anticoagulant;
Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system
Keywords: فاکتور Xa; Factor Xa; Conjugation; Recommender system; Collaborative filtering
Ex vivo reversal of the anticoagulant effects of edoxaban
Keywords: فاکتور Xa; aPTT; Activated partial thromboplastin time; Cmax; Maximum plasma concentration; FEIBA; Factor VIII inhibitor bypass activity; FEU; Fibrinogen equivalent units; FX; Factor X; FXa; Factor Xa; LMWH; Low-molecular-weight heparin; NOACs; Novel oral anticoagul
Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry
Keywords: فاکتور Xa; FXa; factor Xa; PT; prothrombin time; POC; point of care; ROTEM®; rotational thrombelastometry®; LowTF; low-tissue factor; PiCT®; prothrombinase induced clotting time®; DMSO; dimethylsulfoxide; CT; clotting time; CFT; clot formation time; t,MaxVel;
Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor xa
Keywords: فاکتور Xa; ACS; acute coronary syndrome; DVT; deep vein thrombosis; UFH; unfractionated heparin; LMWHs; low-molecular-weight heparins; TAP; tick anticoagulant peptide; PF3; platelet factor 3; DMSO; dimethyl sulfoxide; PT; prothrombin time; FXa; factor Xa; PT2; plasm
Characterization of the protein Z-dependent protease inhibitor interactive-sites of protein Z
Keywords: فاکتور Xa; PZ; protein Z; ZPI; protein Z-dependent protease inhibitor; RCL; reactive center loop; ZPI-Y387A; a ZPI mutant in which Tyr-387 has been replaced with an Ala; FXa; activated factor X; Gla; γ-carboxyglutamic acid; EGF; epidermal growth factor; PZ/FX-LC; a
Sulfated low molecular weight lignins, allosteric inhibitors of coagulation proteinases via the heparin binding site, significantly alter the active site of thrombin and factor xa compared to heparin
Keywords: فاکتور Xa; UFH; unfractionated heparin; LMWH; low molecular weight heparin; fIIa; factor IIa (thrombin); fXa; factor Xa; LMWL; low molecular weight lignin; Sulfated lignins; Heparin; Anticoagulation; Allosteric mechanism; Exosite II; Thrombin;
Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats
Keywords: فاکتور Xa; AF; atrial fibrillation; ED50; dose required for 50% inhibition of thrombus formation; FXa; factor Xa; ICH; intracerebral hemorrhage; PT; prothrombin time; SEM; standard error of mean; VTE; venous thromboembolism; Intracerebral hemorrhage; Factor Xa inhib
Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats
Keywords: فاکتور Xa; APTT; activated partial thromboplastin time; BID; twice daily; DVT; deep vein thrombosis; factor Xa; activated factor X; HE; hematoxylin and eosin; PE; pulmonary embolism; PT; prothrombin time; PTAH; phosphotungstic acid hematoxylin; QD; once daily; S.E.M
Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor
Keywords: فاکتور Xa; AUC; area under the curve; Cl; clearance; DAB; 3,3â²-diaminobenzidine; dIF; double immunofluorescence; EGFR; epidermal growth factor receptor; GAG; glycosaminoglycans; GPI; glycosylphosphatidylinositol; FVIII; Factor VIII; FIX; Factor IX; FXa; Factor Xa;
A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa
Keywords: فاکتور Xa; Anticoagulant peptide; Biosensor analysis; Daboia russelii russelii; Factor Xa inhibitor; Protein-protein interaction; Thrombin inhibitor; ALP; alkaline phosphatase; AT-III; antithrombin-III; BLASTP; basic local alignment search tool; CD; circular dichr
Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation : Insights From the ARISTOTLE Trial
Keywords: فاکتور Xa; antiarrhythmia agents; anticoagulants; antithrombotic agents; factor Xa; stroke; thromboembolism; warfarinAF, atrial fibrillation; CHADS2, congestive heart failure, hypertension, age, diabetes, and stroke; CI, confidence interval; HR, hazard ratio; INR, i
New series of 6-substituted coumarin derivatives as effective factor Xa inhibitors: Synthesis, in vivo antithrombotic evaluation and molecular docking
Keywords: فاکتور Xa; Coumarin; Anticoagulant; Factor Xa; Prothrombin time
Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats
Keywords: فاکتور Xa; APTT; activated partial thromboplastin time; BT2; dose required to double bleeding time; CI; confidence interval; ED50; dose required for 50% inhibition of thrombus formation; FXa; factor Xa; INR; international normalization ratio; iv; intravenous; LMWH;
Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa
Keywords: فاکتور Xa; FXa; factor Xa; PE; pulmonary thromboembolism; VT; venous thrombosis; PT; prothrombin time; aPTT; activated partial thromboplastin time; rFVIIa; recombinant factor VIIa; PCC; prothrombin complex concentrate; ACC; anti-inhibitor coagulant complex; MC; meth
Proteolytic modulation of factor Xa-antithrombin complex enhances fibrinolysis in plasma
Keywords: فاکتور Xa; tPA; tissue plasminogen activator; FXa; factor Xa; AT; antithrombin; Xa33/13; non-covalent heterodimer of 33Â kDa and 13Â kDa FXa fragments; Xa33/13-AT; Xa33/13 covalently linked to AT through Xa13; GEMSA; 2-guanidinoethylmercaptosuccinic acid; PEG; polye
Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores
Keywords: فاکتور Xa; Factor Xa; Platelet fibrinogen receptor; GPIIb/IIIa; Designed multiple ligands; Anticoagulant; Antiaggregant; CDI; 1,1â²-carbonyldiimidazole; DIEA; diisopropylethylamine; DMAP; 4-dimethylaminopyridine; DMF; N,N-dimethylformamide; DMLs; designed multiple
Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin
Keywords: فاکتور Xa; LMWH, Low-molecular-weight-heparinDrug monitoring; Enoxaparin; Factor Xa; Low-molecular-weight heparin
Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation : Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention
Keywords: فاکتور Xa; atrial fibrillation; factor Xa; rivaroxaban; stroke; warfarinAF, atrial fibrillation; CI, confidence interval; CNS, central nervous system; EOS, end of study; HR, hazard ratio; INR, international normalized ratio; MI, myocardial infarction
New oral anticoagulants after acute coronary syndrome
Keywords: فاکتور Xa; antithrombins; anticoagulants; acute coronary syndrome; secondary prevention; factor Xa; thrombin; humans
Protein Z/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue
Keywords: فاکتور Xa; ABC; avidin - biotin complex technique; antibody T2G1; antibody directed to fibrin II (des fibrinopeptide B fibrin); antibody 1-8C6; antibody which reacts with fibrinogen or des fibrinopeptide A fibrin but not with des fibrinopeptide B fibrin; AT; antit
Determination of alpha-2-macroglobulin complexes by a new immuno-activity assay
Keywords: فاکتور Xa; α2M; alpha-2-macroglobulin; H; heparin; α2-AP; alpha-2-antiplasmin; APC; activated protein C; AT; antithrombin; PCI; protein C inhibitor; IIa; thrombin; Xa; factor Xa; PPACK; D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone; Blood coagulation; Alp
Actions of the Kunitz-type serine protease inhibitor Amblyomin-X on VEGF-A-induced angiogenesis
Keywords: فاکتور Xa; Amblyomma cajennense; Chorioallantoic membrane; Dorsal skinfold chamber; Intravital microscopy; PECAM-1; t-End endothelial cell; APP; Alzheimer's amyloid precursor protein; Ambly; Amblyomin-X; CFSE; Carboxyfluorescein diacetate succinimidyl ester; CAM; Ch
Expression and purification of human PYY(3–36) in Escherichia coli using a His-tagged small ubiquitin-like modifier fusion
Keywords: فاکتور Xa; PYY; E. coli; SUMO; Factor Xa; IMAC; HPLC